Financial Performance Highlights
Neimeth International Pharmaceuticals Plc has demonstrated impressive financial growth, reporting a 120 per cent increase in revenue and profitability for the nine months ending January to September 2025. This performance reflects a significant upward trend in the company’s operational efficiency and market presence.
Revenue Growth and Profitability
The company’s interim financial results, submitted to the Nigerian Exchange Limited, reveal that its revenue increased to N5.01bn from N3.09bn during the same period in 2024, marking a 62 per cent rise. This surge in revenue was accompanied by a 71 per cent increase in gross profit, which reached N2.49bn. The operating profit before finance costs also showed remarkable growth, rising to N1.66bn.
Despite the substantial increase in sales revenue, Neimeth managed to control its expenses effectively. Marketing and distribution costs rose by only 6 per cent, increasing from N412.7m to N437.4m. However, administrative costs saw a more significant increase of 67 per cent, even amid high inflation and elevated foreign exchange costs.
Impact of Finance Costs
A notable challenge for the company was the 198 per cent increase in finance costs, which climbed from N442.7m to N1.3bn. This rise in financing expenses had a negative impact on the bottom line. Nevertheless, net profit for the period still managed to grow by nine per cent, reaching N339.8m compared to N310.4m in the previous year.
Balance Sheet and Equity Growth
The company’s balance sheet indicates continued growth. Total assets expanded to N13.35bn, up from N11.99bn at the end of December 2024. Similarly, total liabilities increased to N11.35bn from N10.34bn during the same period.
This growth in assets and liabilities contributed to an improvement in net assets, which rose by 21 per cent to N1.99bn, up from N1.65bn at the start of the period. This increase reflects the profits generated by the company during the year.
The company’s equity base was further strengthened by its profitability. Starting with an opening equity of N1.65bn, the addition of the N339.8m profit for the period brought the total equity to N1.99bn as of 30 September 2025. Earnings Per Share (EPS) for the period stood at 7.95 kobo, an increase from 7.27 kobo in the prior year.
Market Reaction and Investor Confidence
Following its strong performance in operations and profitability, Neimeth International Pharmaceuticals Plc has experienced a significant rebound in its share price in 2025. Investors have reassessed the company based on its emerging results, leading to increased confidence in its future prospects.